Compare GSK plc (GSK) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Yum! Brands, Inc. — how do they compare? GSK plc trades at $46.52 (market cap $91.88B), while Yum! Brands, Inc. trades at $144.69 (market cap $39.02B). The key difference: GSK plc is far larger — about 2.4× Yum! Brands, Inc.'s market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Yum! Brands, Inc. for 132 Days on average.
| GSK | YUM | |
|---|---|---|
Market Cap | $91.88B | $39.02B |
Volume | 7,730,529 | 2,597,636 |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $168.16 |
52-Week Low | $43.24 | $135.77 |
Typical Hold Time | 93 Days | 132 Days |
Enterprise Value | $111.88B | $50.63B |
Dividend Yield | 3.9% | 2.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
YUM stock trades at $145.15, up 3.42% today, with a bullish technical signal and strong support at $141. Revenue grew to $8.21B in 2025, with net income of $1.56B and a 25.4% net margin. The company recently sold Pizza Hut for $1.5B, focusing on KFC and Taco Bell, and declared a $0.75 dividend payable September 18, 2026.
Outlook is positive with a consensus price target of $170.44, though high debt and competitive pressures pose risks. Earnings beat expectations in two of the last three quarters, and cash flow from operations is robust at $2.01B, supporting shareholder returns amid a hold-heavy analyst rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
